Sign In
Buy BDTX
$1.61
-0.0500 (-3.01%)
At Close: Jun 22, 2026
Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data
01:31pm, Wednesday, 03'rd Dec 2025
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) released topline data on Wednesday from its Phase 2 trial of silevertinib in frontline (1L) non-small cell lung cancer (NSCLC) patients with non-classic
CAMBRIDGE, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update
04:01pm, Tuesday, 02'nd Dec 2025
Webcast to be held Wednesday, December 3, at 8:00am ET CAMBRIDGE, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing
Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout
08:57am, Thursday, 20'th Nov 2025
Black Diamond Therapeutics remains undervalued despite recent share price gains, with a promising EGFR inhibitor pipeline targeting unmet needs. Silevertinib, BDTX's lead candidate, is advancing in NS
Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run?
10:16am, Wednesday, 12'th Nov 2025
Black Diamond (BDTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
04:01pm, Thursday, 06'th Nov 2025
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
07:30am, Thursday, 06'th Nov 2025
CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic
Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings?
03:21pm, Friday, 31'st Oct 2025
Black Diamond Therapeutics gears up for Q3 results as investors eye key silevertinib data and additional development plans.
BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?
10:25am, Wednesday, 22'nd Oct 2025
ORIC's diversified oncology pipeline and positive estimate revisions give it an edge over BDTX's silevertinib-focused strategy.
Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?
10:20am, Wednesday, 15'th Oct 2025
Black Diamond Therapeutics focuses on silevertinib, a next-gen EGFR inhibitor for NSCLC, after outlicensing its other lead asset to Servier.
BDTX Stock Hits 52 Week High: Is There More Room for Growth?
10:56am, Thursday, 09'th Oct 2025
Black Diamonds shares surge 86.4% in 2025 as strong silevertinib data and rising estimates fuel optimism for further gains.
Black Diamond Therapeutics, Inc. (BDTX) Hit a 52 Week High, Can the Run Continue?
10:16am, Tuesday, 07'th Oct 2025
Black Diamond (BDTX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
01:56pm, Thursday, 25'th Sep 2025
Black Diamond's silevertinib aims to challenge Tagrisso, offering broad EGFR mutation coverage, as key trial results are expected in late 2025.
BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?
11:26am, Tuesday, 23'rd Sep 2025
BDTX and Cullinan advance next-gen EGFR inhibitors, but silevertinib's potential and valuation tilt momentum toward BDTX.
Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year?
10:40am, Monday, 22'nd Sep 2025
Here is how Black Diamond (BDTX) and Cidara Therapeutics (CDTX) have performed compared to their sector so far this year.
